Showing posts with label recombinant salmon calcitonin. Show all posts
Showing posts with label recombinant salmon calcitonin. Show all posts

Friday, October 26, 2012

Positive Results from Phase 2 Trial of Oral Calcitonin | News | Drug Discovery and Development Magazine

Tarsa Therapeutics Inc. announced that a Phase 2 trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the lumbar spine.  These data were presented at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting by Phase 2 investigator Neil Binkley, MD, who is an associate professor of endocrinology and Geriatrics at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin.....